Bionano Genomics, Inc. (BNGO)

Market Cap	5.52M
Revenue (ttm)	33.33M
Net Income (ttm)	-135.78M
Shares Out	1.70M
EPS (ttm)	-132.48
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	77,001
Open	3.280
Previous Close	3.300
Day's Range	3.220 - 3.290
52-Week Range	3.170 - 72.600
Beta	2.25
Analysts	Hold
Price Target	60.00 (+1,746.15%)
Earnings Date	May 7, 2025

About BNGO

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearizatio...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Aug 21, 2018
• Employees: 344
• Stock Exchange: NASDAQ
• Ticker Symbol: BNGO
• Website: https://www.bionano.com

Financial Performance

In 2023, Bionano Genomics's revenue was $36.12 million, an increase of 29.90% compared to the previous year's $27.80 million. Losses were -$232.49 million, 75.3% more than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for BNGO stock is "Hold." The 12-month stock price forecast is $60.0, which is an increase of 1,746.15% from the latest price.

Price Target

$60.0

(1,746.15% upside)

Analyst Consensus: Hold